• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    15.64 -1.49 (-8.70%)
    Delayed Quote Updated: 3:10 PM EDT, Oct 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,764,483
    Open 16.79
    Bid (Size) 15.63 (300)
    Ask (Size) 15.64 (700)
    Prev. Close 17.13
    Today's Range 15.58 - 16.79
    52wk Range 12.07 - 29.23
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
    From Summit Therapeutics
    Via Business Wire

    Performance

    52-Week Range 46.5% below 52-week high
    15.64
    12.0752W Low 29.2352W High
    1 Week 14.7% below 1-week high
    16.531W Low 18.331W High

    Summit Therapeutics Inc. - Common Stock (SMMT) traded between $12.07 and $29.23 over the past 52 weeks and last traded at $15.64, 46.5% below its 52-week high. Over the past week it ranged between $16.53 and $18.33.

    Past 12 Months
    -9.6%
    -15.1%
    +2.2%
    -21.9%
    -10.7%
    -31.8%
    1W -$1.67
    1M -$2.78
    3M +$0.34
    6M -$4.39
    YTD -$1.88
    1Y -$7.29

    SMMT was -31.8% over the past year, -21.9% over six months, -10.7% year to date, -9.6% in the last week.

    12 Months vs Market
    SMMT
    -31.8%
    DIA
    +12.2%
    SPY
    +17.4%
    QQQ
    +23.4%
    IWM
    +13.4%

    Over the past 12 months SMMT returned -31.8% versus DIA (Dow) +12.2%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +23.4% and IWM (Russell 2000) +13.4%.

    Volume & Liquidity 0.82× 3-mo avg
    Today 4,764,483 3-mo avg 5.8M
    1W
    6.1M
    1M
    7.4M
    3M
    5.8M
    6M
    5.7M
    YTD
    4.6M
    1Y
    4.2M

    SMMT most recently traded 4,764,483 shares against a 3-month average daily volume of 5.8M.

    More News

    Read More
    These stocks that are showing activity before the opening bell on Tuesday. ↗
    Via Chartmill
    News headline image
    AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
    From Summit Therapeutics
    Via Business Wire
    Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗
    Via Chartmill
    News headline image
    HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
    From Summit Therapeutics
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
    From Summit Therapeutics
    Via Business Wire
    News headline image
    GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗
    Via The Motley Fool
    News headline image
    Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    News headline image
    Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Summit Therapeutics Announces Proposed Public Offering of Common Stock
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
    From Summit Therapeutics
    Via Business Wire

    Frequently Asked Questions

    Is Summit Therapeutics Inc. - Common Stock publicly traded?
    Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Summit Therapeutics Inc. - Common Stock trade on?
    Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
    The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
    What is the current price of Summit Therapeutics Inc. - Common Stock?
    The current price of Summit Therapeutics Inc. - Common Stock is 15.64
    When was Summit Therapeutics Inc. - Common Stock last traded?
    The last trade of Summit Therapeutics Inc. - Common Stock was at 10/13/26 03:10 PM ET
    What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
    The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.52B
    How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
    Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.